Technical Analysis for PCRX - Pacira Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 59.96 -1.69% -1.03
PCRX closed down 1.69 percent on Tuesday, August 11, 2020, on approximately normal volume. The bulls were able to push the stock to a new 52-week high. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical PCRX trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
New 52 Week Closing High Bullish -1.69%
Pocket Pivot Bullish Swing Setup -1.69%
New 52 Week High Strength -1.69%
Upper Bollinger Band Walk Strength -1.69%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Medicine Health Cancer Pharmaceutical Pain Surgery Pharmaceutical Products Pharmacology Rheumatoid Arthritis Dosage Forms Piperidines Drug Delivery Technology Bupivacaine Liposome Surgical Site

Is PCRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 62.25
52 Week Low 27.46
Average Volume 797,667
200-Day Moving Average 44.20
50-Day Moving Average 51.40
20-Day Moving Average 55.33
10-Day Moving Average 56.22
Average True Range 2.33
ADX 17.74
+DI 27.95
-DI 15.30
Chandelier Exit (Long, 3 ATRs ) 55.25
Chandelier Exit (Short, 3 ATRs ) 58.48
Upper Bollinger Band 60.29
Lower Bollinger Band 50.38
Percent B (%b) 0.97
BandWidth 17.90
MACD Line 2.00
MACD Signal Line 1.55
MACD Histogram 0.4538
Fundamentals Value
Market Cap 2.42 Billion
Num Shares 40.4 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -34.86
Price-to-Sales 4.67
Price-to-Book 5.03
PEG Ratio -3.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.70
Resistance 3 (R3) 64.04 63.15 63.07
Resistance 2 (R2) 63.15 62.20 62.97 62.86
Resistance 1 (R1) 61.55 61.61 61.11 61.21 62.66
Pivot Point 60.66 60.66 60.43 60.48 60.66
Support 1 (S1) 59.06 59.71 58.62 58.72 57.26
Support 2 (S2) 58.17 59.12 57.99 57.06
Support 3 (S3) 56.57 58.17 56.85
Support 4 (S4) 56.23